ABVC BioPharma, Inc. (ABVC) stock
ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
$0.91−0.03 (-3.15%)
Close on Nov 18, 2026Market cap $24.27MP/E –Yield –
ABVC BioPharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ABVC BioPharma's revenue for the twelve months ending Dec 31, 2024 was $296.00K, up 94.2% year over year. For fiscal 2025 it was $296.00K, up 0.0% from the year before. Over ten years it grew 57.3% a year on average. The highest annual figure on record is $969.78K in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.00K | 0.0% |
| FY2024 | Dec 31, 2024 | $296.00K | +94.2% |
| FY2023 | Dec 31, 2023 | $152.43K | -84.3% |
| FY2022 | Dec 31, 2022 | $969.78K | +172.6% |
| FY2021 | Dec 31, 2021 | $355.80K | -26.3% |
| FY2020 | Dec 31, 2020 | $483.05K | -31.2% |
| FY2019 | Dec 31, 2019 | $701.72K | – |
| FY2014 | Sep 18, 2014 | $0 | -100.0% |
| FY2013 | Sep 30, 2013 | $7.79K | +36.3% |
| FY2012 | Sep 30, 2012 | $5.71K | +79.1% |
| FY2011 | Sep 30, 2011 | $3.19K | -78.5% |
| FY2010 | Sep 30, 2010 | $14.86K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $795.95K | +65953.9% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $1.97K | -9.2% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $389.28K | +2350.7% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $117.14K | +1817.5% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $1.21K | -99.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $2.17K | -99.6% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $15.88K | -62.4% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $6.11K | -98.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $128.27K | +399.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $588.99K | +494.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $42.27K | +34.4% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $312.86K | +18.9% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $25.66K | -58.7% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $99.00K | -14.3% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $31.44K | -86.1% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $263.15K | +234.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $62.19K | -37.8% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $115.55K | -41.6% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $226.51K | +18.1% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $78.79K | -62.9% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $99.96K | +11.1% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $197.73K | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $191.78K | +174.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $212.24K | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $90.00K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $0 | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $70.00K | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | $0 | – |
See a number that looks wrong?